Should I buy or sell Corbus Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRBP shares. View CRBP analyst ratings or view top-rated stocks .

What is Corbus Pharmaceuticals' stock price target for 2024?

2 equities research analysts have issued twelve-month price objectives for Corbus Pharmaceuticals' stock. Their CRBP share price targets range from $46.00 to $58.00. On average, they expect the company's stock price to reach $52.00 in the next twelve months. This suggests a possible upside of 42.3% from the stock's current price. View analysts price targets for CRBP or view top-rated stocks among Wall Street analysts .

How have CRBP shares performed in 2024?

Corbus Pharmaceuticals' stock was trading at $6.04 at the start of the year. Since then, CRBP stock has increased by 504.8% and is now trading at $36.53. View the best growth stocks for 2024 here .

Are investors shorting Corbus Pharmaceuticals?

Corbus Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 475,600 shares, an increase of 17.8% from the March 15th total of 403,800 shares. Based on an average trading volume of 912,800 shares, the days-to-cover ratio is presently 0.5 days. Approximately 4.6% of the shares of the stock are sold short. View Corbus Pharmaceuticals' Short Interest .

When is Corbus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our CRBP earnings forecast .

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) posted its quarterly earnings data on Tuesday, March, 12th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.36) by $0.55.

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V) , HP (HPQ) , Fortive (FTV) , Lowe's Companies (LOW) , Sorrento Therapeutics (SRNE) , Exelixis (EXEL) , Matinas BioPharma (MTNB) , Inovio Pharmaceuticals (INO) and KushCo (KSHB) .

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CRBP

Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis

→ Don’t expose yourself to stocks during the week (From DTI) (Ad)

Free CRBP Stock Alerts

$36.53

-0.63 (-1.70%)

(As of 04/18/2024 ET)

Compare

Today's Range: $35.26
▼
$37.78
50-Day Range: $22.00
▼
$47.08
52-Week Range: $3.03
▼
$49.87

Volume: 128,015 shs
Average Volume: 815,362 shs
Market Capitalization: $383.93 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $52.00

Get Corbus Pharmaceuticals alerts:

Corbus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 42.3% Upside
$52.00 Price Target
Short Interest: Healthy
4.58% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.65
Upright™ Environmental Score
News Sentiment: 1.11
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$33.37 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($5.21) to ($5.12) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.43 out of 5 stars

Medical Sector

93rd out of 918 stocks

Pharmaceutical Preparations Industry

26th out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
Corbus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Corbus Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.58% of the float of Corbus Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Corbus Pharmaceuticals has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Corbus Pharmaceuticals has recently increased by 17.78%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Corbus Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Corbus Pharmaceuticals does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Corbus Pharmaceuticals has received a 73.92% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for Corbus Pharmaceuticals is -0.65.

2.8

News and Social Media Coverage

News Sentiment
Corbus Pharmaceuticals has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Corbus Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 7 people have searched for CRBP on MarketBeat in the last 30 days. This is a decrease of -61% compared to the previous 30 days.
MarketBeat Follows
Only 8 people have added Corbus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Corbus Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $33,374,556.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 4.00% of the stock of Corbus Pharmaceuticals is held by insiders.
Percentage Held by Institutions
64.64% of the stock of Corbus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Corbus Pharmaceuticals are expected to grow in the coming year, from ($5.21) to ($5.12) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Corbus Pharmaceuticals is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Corbus Pharmaceuticals is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Corbus Pharmaceuticals Stock (NASDAQ:CRBP)

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

CRBP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CRBP Stock News Headlines

April 16, 2024 | msn.com

Here's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price Strength

April 16, 2024 | americanbankingnews.com

Short Interest in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Expands By 17.8%

April 18, 2024 | Darwin (Ad)

2024's Must-Have Guide: Master Crypto Investment Today

The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

April 12, 2024 | americanbankingnews.com

Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Crosses Above 50 Day Moving Average of $33.45

April 2, 2024 | globenewswire.com

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

March 22, 2024 | nasdaq.com

CRBP Factor-Based Stock Analysis

March 17, 2024 | 247wallst.com

Buffett Can't Get Enough of This Stock, Plus Other Insider Buying

March 13, 2024 | msn.com

Corbus Pharmaceuticals files for $300M mixed shelf offering

April 18, 2024 | Priority Gold (Ad)

Biden to Launch “FedNOW” [Move Your Money Now]

Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...

March 12, 2024 | finanznachrichten.de

Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

March 12, 2024 | globenewswire.com

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

March 11, 2024 | finance.yahoo.com

CRBP Apr 2024 25.000 put

March 11, 2024 | finance.yahoo.com

CRBP Mar 2024 45.000 put

March 10, 2024 | finance.yahoo.com

CRBP Jun 2024 50.000 put

March 10, 2024 | finance.yahoo.com

CRBP Jun 2024 50.000 call

March 8, 2024 | investorplace.com

All Three of Our Analysts Agree

March 7, 2024 | finance.yahoo.com

CRBP Mar 2024 40.000 call

March 6, 2024 | realmoney.thestreet.com

Corbus Pharmaceuticals just upgraded at Jefferies, here's why

March 6, 2024 | globenewswire.com

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

February 28, 2024 | markets.businessinsider.com

Corbus Pharmaceuticals Names Dominic Smethurst CMO

February 28, 2024 | globenewswire.com

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

February 25, 2024 | finance.yahoo.com

Corbus Pharmaceuticals Holdings Inc (3371.MU)

February 18, 2024 | finance.yahoo.com

ACAD Mar 2024 35.000 put

February 17, 2024 | finance.yahoo.com

ACAD Mar 2024 36.000 call

February 7, 2024 | msn.com

Corbus Pharmaceuticals Announces Chief Scientific Officer Resignation

February 6, 2024 | finance.yahoo.com

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 6, 2024 | msn.com

Corbus Pharmaceuticals Shares Updated Corporate Insights

See More Headlines

Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/12/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CRBP
CUSIP: N/A
CIK: 1595097
Web: www.corbuspharma.com
Phone: (617) 963-0100
Fax: 617-663-6085
Employees: 19
Year Founded: 2009

Price Target and Rating

Average Stock Price Target: $52.00
High Stock Price Target: $58.00
Low Stock Price Target: $46.00
Potential Upside/Downside: +42.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($10.37)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-44,600,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -920.31%
Return on Assets: -111.56%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.74
Quick Ratio: 0.74

Sales & Book Value

Annual Sales: $880,000.00
Price / Sales: 436.28
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.56) per share
Price / Book: -23.42

Miscellaneous

Outstanding Shares: 10,510,000
Free Float: 10,087,000
Market Cap: $383.93 million
Optionable: Optionable
Beta: 2.46

Social Links

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Yuval Cohen Ph.D. (Age 49)
CEO & Director
Comp: $907.78k
Mr. Sean F. Moran CPA (Age 66)
M.B.A., Chief Financial Officer
Comp: $609.28k
Ms. Lindsey Smith
Head of Corporate Communications & Patient Advocacy
Ms. Christina Bertsch
Head of Human Resources
Dr. Dominic Smethurst M.A. (Age 49)
M.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CRBP Stock Analysis - Frequently Asked Questions

Should I buy or sell Corbus Pharmaceuticals stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRBP shares.
View CRBP analyst ratings or view top-rated stocks.
What is Corbus Pharmaceuticals' stock price target for 2024?: 2 equities research analysts have issued twelve-month price objectives for Corbus Pharmaceuticals' stock. Their CRBP share price targets range from $46.00 to $58.00. On average, they expect the company's stock price to reach $52.00 in the next twelve months. This suggests a possible upside of 42.3% from the stock's current price.
View analysts price targets for CRBP or view top-rated stocks among Wall Street analysts.
How have CRBP shares performed in 2024?: Corbus Pharmaceuticals' stock was trading at $6.04 at the start of the year. Since then, CRBP stock has increased by 504.8% and is now trading at $36.53.
View the best growth stocks for 2024 here.
Are investors shorting Corbus Pharmaceuticals?: Corbus Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 475,600 shares, an increase of 17.8% from the March 15th total of 403,800 shares. Based on an average trading volume of 912,800 shares, the days-to-cover ratio is presently 0.5 days. Approximately 4.6% of the shares of the stock are sold short.
View Corbus Pharmaceuticals' Short Interest.

When is Corbus Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our CRBP earnings forecast.
How were Corbus Pharmaceuticals' earnings last quarter?: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) posted its quarterly earnings data on Tuesday, March, 12th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.36) by $0.55.
What other stocks do shareholders of Corbus Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and KushCo (KSHB).
How do I buy shares of Corbus Pharmaceuticals?: Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRBP) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial